Recent Company News

• 04:46 PM ET Aug 11, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:17 AM ET Aug 12, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 09:55 PM ET Aug 12, 2026
  

  Belite Bio reports Q2 EPS ($0.70) vs FactSet ($0.78) [7 est, ($0.99)-(0.54)] ($178.94, 0.00)

• 04:03 PM ET Aug 11, 2026
  

  Belite Bio announces FDA acceptance and priority review of NDA for tinlarebant for the treatment of Stargardt disease type 1 ($177.58, 0.00)

• 04:19 PM ET Jul 22, 2026
  

  Transcript Intelligence: Belite Bio at H.C. Wainwright Ophthalmology Virtual Conference - Panel ($157.14, -3.94)

• 08:07 AM ET Jul 20, 2026
  

  Belite Bio announces additional secondary endpoint data from phase 3 trial of tinlarebant in Stargardt disease type 1 ($150.08, 0.00)

• 01:17 PM ET Jul 09, 2026
  

  Transcript Intelligence: Belite Bio at Piper Sandler Virtual Ophthalmology Investor Symposium ($152.01, -0.29)